Byonyks has received U.S. FDA 510(k) clearance for its X1 Automated Peritoneal Dialysis (APD) Cycler, marking a significant milestone in the company’s mission to expand access to safe, reliable, and more affordable home-based dialysis technologies.
Having already demonstrated success with 10,000+ therapies worldwide through its overseas licenses, Byonyks is now planning to enter the U.S. market under the leadership of Founder and CEO Farrukh Usman. The company’s initial rollout will focus on California, Texas, and Illinois.
The X1 APD Cycler is designed to deliver automated peritoneal dialysis therapy at home, supporting patients requiring long-term renal replacement therapy while reducing the burden of in-center treatment. Peritoneal dialysis is a bloodless therapy that offers patients greater flexibility, an improved quality of life, and helps preserve residual kidney function for longer. Data from the U.S. Renal Data System show that peritoneal dialysis has a 10% higher survival rate than in-center hemodialysis — yet 85% of Americans on dialysis do not currently receive it.
Globally, approximately 86% of people who need dialysis lack access to it. Byonyks is committed to changing that through innovation that expands global access to dialysis, improves biocompatibility, minimizes metabolic impact, reduces infection risk, and lowers the carbon footprint.
This press release was originally distributed via GlobeNewswire and covered by the following outlets:
- GlobeNewswire — https://www.globenewswire.com/news-release/2026/02/03/3230967/0/en/Byonyks-X1-Revolutionizing-Dialysis-Now-FDA-Cleared-and-Planning-to-start-Patients-in-the-U-S.html
- Yahoo Finance — https://finance.yahoo.com/news/byonyks-x1-revolutinizing-dialysis-now-130000576.html
- Business Insider Markets — https://markets.businessinsider.com/news/stocks/byonyks-x1-revolutinizing-dialysis—now-fda-cleared-and-planning-to-start-patients-in-the-u-s-1035778112
- Times of San Diego — https://pr.timesofsandiego.com/article/Byonyks-X1-Revolutinizing-Dialysis-Now-FDA-Cleared-and-Planning-to-start-Patients-in-the-US?storyId=6981f238513d4aa34822fedb
- Bogalusa Daily News — https://smb.bogalusadailynews.com/article/Byonyks-X1-Revolutinizing-Dialysis-Now-FDA-Cleared-and-Planning-to-start-Patients-in-the-US?storyId=6981f238513d4aa34822fedb
- Financial Content (Silicon Valley) — https://markets.financialcontent.com/siliconvalley/article/gnwcq-2026-2-3-byonyks-x1-revolutinizing-dialysis-now-fda-cleared-and-planning-to-start-patients-in-the-us
- Financial Content (Daily Bulletin) — https://markets.financialcontent.com/dailybulletin/article/gnwcq-2026-2-3-byonyks-x1-revolutinizing-dialysis-now-fda-cleared-and-planning-to-start-patients-in-the-us
- BioSpace — https://www.biospace.com/press-releases/byonyks-x1-revolutionizing-dialysis-now-fda-cleared-and-planning-to-start-patients-in-the-u-s
- Home Health Provider — https://www.homehealthprovider.com/doc/byonyks-x-revolutionizing-dialysis-now-fda-cleared-and-planning-to-start-patients-in-the-u-s-0001
For more information, visit www.byonyks.com
Contact: Maheen Sami, Head of Investor Relations — [email protected]